Recently, Regeneron ( REGN -1.41%) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its ...

Regeneron Pharmaceuticals said it will acquire 23andMe's business. What happened to 23andMe? Should you delete your data?

Regeneron said it will acquire 23andMe’s genomics service and its bank of 15 million customers’ personal and genetic data as ...

Regeneron will acquire 23andMe’s core assets for $256 million, ensuring customer data privacy and continuing the mission of ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's ...

Regeneron is acquiring "substantially all" of 23andMe's assets for $256 million following a bankruptcy auction.

Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations.

Tarrytown-based Regeneron would acquire 23andMe for $256 million under the deal that is pending approval by bankruptcy court and regulators. New York-based biotech giant Regeneron Pharmaceuticals ...

On May 19, Regeneron agreed to acquire 23andMe for $256 million. The potential acquisition is still subject to bankruptcy court approval. At its peak, 23andMe's market value swelled to $5.8 billion.

Regeneron acquires 23andMe's genetics services for (Dollar) 256 million * Customer privacy safeguards will remain in place ...

Is Regeneron a good stock to buy now in light of a potential 23andMe acquisition? Here's a quick look at what it's paying for to find out. 23andMe's market cap peaked at $5.8 billion a few months ...